We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

153 hedge funds and large institutions have $396M invested in Sciclone Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 55 increasing their positions, 49 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

544% more call options, than puts

Call options by funds: $290K | Put options by funds: $45K

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 49

1% more funds holding

Funds holding: 151153 (+2)

0% less capital invested

Capital invested by funds: $396M → $396M (-$505K)

Holders
153
Holders Change
+2
Holders Change %
+1.32%
% of All Funds
3.83%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
29
Increased
55
Reduced
49
Closed
23
Calls
$290K
Puts
$45K
Net Calls
+$245K
Net Calls Change
+$171K
Name Holding Trade Value Shares
Change
Change in
Stake
BFA
1
BlackRock Fund Advisors
California
$49.5M -$2.77M -276,603 -6%
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$31.2M +$118K +11,751 +0.4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$29.2M +$965K +96,541 +4%
NCM
4
Nantahala Capital Management
Connecticut
$23.4M +$3.99M +399,485 +23%
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$20.7M -$658K -65,850 -3%
Renaissance Technologies
6
Renaissance Technologies
New York
$19.1M +$3.85M +384,898 +28%
BIT
7
BlackRock Institutional Trust
California
$17.3M -$85.2K -8,522 -0.5%
State Street
8
State Street
Massachusetts
$15.5M -$207K -20,722 -1%
SCM
9
Stonepine Capital Management
Oregon
$13.5M +$12.5M +1,249,200 New
NI
10
Numeric Investors
Massachusetts
$10.1M -$16.2M -1,624,926 -64%
AQR Capital Management
11
AQR Capital Management
Connecticut
$9.04M -$421K -42,058 -5%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$8.67M +$610K +60,991 +8%
Northern Trust
13
Northern Trust
Illinois
$8.5M +$119K +11,941 +2%
Charles Schwab
14
Charles Schwab
California
$5.38M +$109K +10,887 +2%
JP Morgan Chase
15
JP Morgan Chase
New York
$5.08M +$4.66M +466,260 +10,225%
QI
16
QS Investors
New York
$4.83M -$1.82M -182,078 -29%
SI
17
Sensato Investors
California
$4.63M -$3.99M -399,183 -48%
American Century Companies
18
American Century Companies
Missouri
$4.63M +$936K +93,638 +28%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$4.28M +$219K +21,874 +6%
Morgan Stanley
20
Morgan Stanley
New York
$4.19M -$20.3K -2,035 -0.5%
Principal Financial Group
21
Principal Financial Group
Iowa
$4.17M +$225K +22,484 +6%
BA
22
BlackRock Advisors
Delaware
$3.77M -$290K -28,958 -8%
Goldman Sachs
23
Goldman Sachs
New York
$3.73M +$224K +22,372 +7%
LSV Asset Management
24
LSV Asset Management
Illinois
$3.46M -$1.64M -163,568 -34%
AllianceBernstein
25
AllianceBernstein
Tennessee
$3.46M +$18.9K +1,890 +0.6%

SCLN Hedge Fund Activity: Q4 2016 in Review

153 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2016, worth a combined $396M — down 0.13% from $396M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SCLN positions and 23 closed out — a net gain of 6 holders — while 55 added to existing stakes and 49 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $12.5M. The largest seller was Numeric Investors, cutting an estimated $16.2M.

  • 153 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2016, up from 151 in Q3 2016.
  • Funds reported $396M of Sciclone Pharmaceuticals Inc stock for Q4 2016, down 0.13% quarter-over-quarter.
  • 29 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2016 and 23 closed out, a net change of +6 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2016 was Stonepine Capital Management, an estimated $12.5M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2016 was Numeric Investors, an estimated $16.2M sold.

Based on aggregated 13F filings for Q4 2016.